Nuveen Asset Management LLC Sells 184,836 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Nuveen Asset Management LLC lessened its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,735,743 shares of the company's stock after selling 184,836 shares during the period. Nuveen Asset Management LLC owned about 0.88% of Amneal Pharmaceuticals worth $21,667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of AMRX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $81,000. Straightline Group LLC acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $92,000. Brevan Howard Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $107,000. Cibc World Markets Corp acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $118,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $121,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Up 0.1%

NASDAQ AMRX traded up $0.01 during trading on Thursday, hitting $7.22. 228,526 shares of the company traded hands, compared to its average volume of 1,441,539. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.29 and a 12 month high of $9.48. The business has a fifty day simple moving average of $7.53 and a 200 day simple moving average of $8.03. The company has a market capitalization of $2.26 billion, a P/E ratio of -10.61 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on AMRX shares. Barclays increased their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $11.50.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.45% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.